Thursday, March 06, 2025 6:33:56 PM
The list of Sarissa companies was disclosed in the Proxy. Link below.
https://www.sec.gov/Archives/edgar/data/897448/000114036123005062/ny20006859x14_dfan14a.htm
As for shares...
https://fintel.io/so/us/amrn/sarissa-capital-management-lp
In his last 13D filed back in 2023, he reports a controlling interest in 33.4M shares. There hasn't been a more recent 13D reporting a change of more than 1%, so he still has control of 33.4M shares +/- 4 million shares.
In the 13F list on the link, you can see what Sarissa holds in their main LP, Sarissa Capital ~24M as of last reporting. There has to be ~9M shares in some other company or advisory account he controls. You can see how Denner moved 19M shares December 2022 out of his LP. This is when he loaded up his various sub accounts before the proxy. A financial "sale" on his books cause he moved them thru his prime broker. Remember everyone here was hopping up and down when MS or whichever one it was, I forget, reported a pickup of 19M shares on their 13F thinking they were investing in Amarin. No... it was just Denner shuffling shares. The 19M sale to himself cut his cost basis as he booked a loss given the share price at the time, and he most likely used it to offset gains for the year. Ultimately, he kept control of the shares which is why he didn't report a disposition of shares on a 13D at that time and told everyone "we've never sold a share". This is why his initial buy price is irrelevant and likely no longer his actual basis on his shares. He's been using and moving those shares. Every year is a new year for him and his crew, not like your IRA. Amarin's been a nice tax mule for him for 2+ years.
In 2024, he moved a majority from his sub accounts back into to his LP. Probably why you see MS showing a few million shares of Amarin every now and then. Same program just in reverse. But still should have around 33M shares under his thumb or he's violating SEC 13D filing regs and he's got a history of not caring about SEC rules.
https://www.sec.gov/Archives/edgar/data/897448/000114036123005062/ny20006859x14_dfan14a.htm
As for shares...
https://fintel.io/so/us/amrn/sarissa-capital-management-lp
In his last 13D filed back in 2023, he reports a controlling interest in 33.4M shares. There hasn't been a more recent 13D reporting a change of more than 1%, so he still has control of 33.4M shares +/- 4 million shares.
In the 13F list on the link, you can see what Sarissa holds in their main LP, Sarissa Capital ~24M as of last reporting. There has to be ~9M shares in some other company or advisory account he controls. You can see how Denner moved 19M shares December 2022 out of his LP. This is when he loaded up his various sub accounts before the proxy. A financial "sale" on his books cause he moved them thru his prime broker. Remember everyone here was hopping up and down when MS or whichever one it was, I forget, reported a pickup of 19M shares on their 13F thinking they were investing in Amarin. No... it was just Denner shuffling shares. The 19M sale to himself cut his cost basis as he booked a loss given the share price at the time, and he most likely used it to offset gains for the year. Ultimately, he kept control of the shares which is why he didn't report a disposition of shares on a 13D at that time and told everyone "we've never sold a share". This is why his initial buy price is irrelevant and likely no longer his actual basis on his shares. He's been using and moving those shares. Every year is a new year for him and his crew, not like your IRA. Amarin's been a nice tax mule for him for 2+ years.
In 2024, he moved a majority from his sub accounts back into to his LP. Probably why you see MS showing a few million shares of Amarin every now and then. Same program just in reverse. But still should have around 33M shares under his thumb or he's violating SEC 13D filing regs and he's got a history of not caring about SEC rules.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
